Purpose of review To describe the principles of photodynamic diagnosis (PDD), narrow-band imaging (NBI) and Storz Professional Image Enhancement System (SPIES) techniques for the endoscopic management of nonmuscleinvasive bladder cancer (BCa) and to report their impact on clinical practice.
INTRODUCTION
Worldwide, bladder cancer (BCa) is the ninth most commonly diagnosed malignancy and the 13th cause of cancer deaths in 2015 [1] . Nearly 70% of newly diagnosed BCa patients present with nonmuscle-invasive BCa (NMIBC); Ta, T1 and carcinoma in situ (CIS) [2] . NMIBC is characterized by high rates of disease recurrence with 15-70% of patients experiencing disease recurrence at 1 year. Disease progression can happen in approximately 30% of high-risk NMIBC within 5 years of their initial transurethral resection of the bladder (TURB) [3, 4] . It has been estimated that approximately 10-20% of bladder tumors are missed by conventional white-light endoscopic imaging (WLI) [5] . Therefore, novel endoscopic imaging techniques needed to improve the detection rates of BCa thereby allowing more accurate diagnosis and consequently improved prognosis. agent such as 5-aminolevulinic acid (5-ALA) or hexylaminolevulinate (HAL) which preferentially metabolite and therefore accumulate in neoplastic cells [7] . Narrow-band imaging (NBI) is an optical technology based on the ability to filter the standard white light into two bandwidths of illumination improving the contrast among epithelial and subepithelial tissue as well as its vascularization. Therefore, the submucosal capillaries of papillary tumors and the superficial vasculature of CIS are highlighted allowing higher visibility including better tumor margin demarcation [8] . Based on similar principle, the Storz Professional Image Enhancement System (SPIES) imaging software platform has been developed to provide clearer images to reduce the rate of false-positive and negative results [9 & ]. This technology uses different light wavelengths to enhance specific color renderings, local brightness and sharpness of the image.
We sought to describe the principles and mechanisms of PDD, NBI and SPIES technologies in the endoscopic management of NMIBC. Furthermore, we aimed to report the impact of these technologies on the detection rate and oncologic outcomes focusing on the published literature of the last 18 months. Finally, we summarized the current clinical indications for the use of these novel endoscopic imaging techniques in NMIBC.
PHOTODYNAMIC DIAGNOSIS
The use of PDD in BCa diagnosis was first described in 1964 by Whitmore et al. [6] . Nevertheless, this endoscopic imaging technique was not introduced into clinical practice until 1994 when Kriegmair et al. [7] reported on 68 patients who were diagnosed with BCa using fluorescence cystoscopy with 5-ALA as photosensitizing agent. 5-ALA and its derivative HAL (Hexvix, IPSEN, Oslo, Norway) are the prodrugs of heme biosynthesis pathway. The protoporphyrin IX (PPIX) is the immediate precursor of heme and is the only intermediate of the pathway that is photoexcited. PPIX appears red using blue-violet light of 600-740-nm wavelength [10] . Normally, a negative feedback on these molecules in the heme pathway prevents the accumulation of PPIX, but the intravesical administration of the prodrug overcomes this problem. The high sensitivity of PDD in detecting BCa relies on the selective accumulation of PPIX (up to 10 times) in neoplastic cells compared with nonneoplastic cells [10] . Consequently, the tumor emits red fluorescence, whereas the normal bladder mucosa appears blue-green. Indeed, CIS appears as a red mucosal patch on the blue-green healthy mucosa background.
The procedure requires distinct scopes, a specific D-Light source and a switch on the head camera or a pedal to shift between white and blue light during cystoscopy as well as during TURB. Furthermore, patients receive a urinary catheterization prior to the procedure for the instillation of the photosensitizing agent. PDD high tolerability and a low rate of adverse events even when used repeatedly [11 && ]. In a critical review of literature that included 26 PDD studies using 5-ALA, 15 studies using HAL and three studies using both reported a moderately strong evidence that PDD improved the tumor detection rate resulting in lower residual disease after TURB compared with WLI [12] . Moreover, PDD was improved recurrence-free survival (RFS) but not progression-free survival. A meta-analysis of six prospective studies showed a significantly higher detection rate of Ta tumors and CIS lesion using PDD compared with WLI [pooled odds ratio (OR) 4.90; 95% confidence interval (CI) 1.94-12.39 and OR 12.37; 95% CI 6.343-24.13, respectively] [13] .
In a network meta-analysis of 15 randomized clinical trials (RCTs), the recurrence rate was lower when 5-ALA-based PDD was used compared with HAL-based PDD (pooled OR 0.48, 95% CI 0.26-0.95) [14] . Of note, the recurrence rate was not significantly different when NBI was used (pooled OR ¼ 0.53, 95% CI 0.26-1.09). These three techniques resulted in a significantly lower recurrence rate compared with WLI. However, the progression rate was comparable among three methods [14] . Conversely, a recent meta-analysis of four RCTs and one retrospective study showed a significantly lower progression rate in patients treated with HAL-based PDD compared with WLI only (pooled OR 1.64, 1.10-2.45) [15 && ]. Recently, Kamat et al. reanalyzed data from a phase III study [16] that evaluated the
KEY POINTS
The PDD requires preoperative instillation of photosensitizing agents such as 5-aminolevulinic acid and hexyl-aminolevulinate. The PDD is associated with an increased sensitivity of detecting bladder tumors and a lower recurrence rate in comparison with white-light imaging.
The NBI is an integrated diagnostic tool enhancing the contrast between the hypervascular BCa and normal mucosa. The suggested reduced recurrence rate compared with white-light imaging has not been fully determined yet.
The SPIES is a diagnostic tool that incorporates four different visualization modes to increase the quality of the image according to different clinical situations. The clinical outcomes of patients treated with SPIES-guided transurethral resection of the bladder are still pending. impact of improved detection of NMIBC using HALbased cystoscopy [17 && ] using a new definition of progression proposed by the International Bladder Cancer Group [18] . There was a trend toward a lower rate of progression in the HAL group, particularly in those progressing from Ta to CIS [17 && ]. In addition, time to progression was longer. Indeed, further powered RCTs are needed to define the role of PDD on progression-free survival.
Novel endoscopic visualization techniques
Results of the impact of PDD-guided TURB on survival outcomes after radical cystectomy are inconsistent. A retrospective analysis of 224 patients treated with radical cystectomy for BCa showed that the use of PDD-guided TURB was an independent predictor of better cancer-specific survival (CSS), RFS and overall survival (OS) [19] . On the other hand, a more recent multicenter study of more than 500 patients did not find an association between the use of PDD during primary or final TURB with CSS or OS after radical cystectomy [20 & ].
NARROW-BAND IMAGING
The NBI is a diagnostic endoscopic light technology introduced by Olympus Corporation (Tokyo, Japan). It is integrated into the camera head or in the cysto/ureteroscope. The NBI devices filter out the red spectrum from white light, resulting in blue and green spectra absorbed by hemoglobin. The two bands differently enter into the mucosa and enhance the contrast between hypervascular tissue and normal bladder mucosa improving the visualization of tumor neoangiogenesis [8] . The shorter blue (415 nm) and the long green (540 nm) bands enter into the superficial and deeper mucosa layers, respectively. The shorter blue band results in a brown-black appearance of the more superficial capillary vessels, whereas the longer green band results in a green appearance of the submucosal vessels. Therefore, papillary tumors appear as brown-green lesions because of the enhanced submucosal capillaries, whereas CIS appears as a dark brown lesion because of the enhanced dense superficial vasculature.
NBI at first appearance seems to give a subjective impression of abnormal areas of bladder mucosa; however, the detection rate with NBI has not been significantly associated with a learning curve of the surgeon [21, 22] . In a prospective comparison of 103 procedures where patients were submitted to WLI and NBI followed by endoscopic resection of all suspicious areas, Cauberg et al. [23] reported a significantly higher detection rate for NBI compared with WLI (95 vs. 79%, respectively; P < 0.001). In a prospective study analysing more than 300 biopsies identified as potentially abnormal by NBI and/or WLI cystoscopy, 30 biopsies were identified as CIS [24] . The estimated sensitivity for detecting CIS was 90% for NBI and 50% for WLI, and the negative predictive value was 87.2% for NBI and 61.3% for WLI, respectively (both P < 0.01). Conversely, no significant difference was found between the two techniques in terms of specificity and positive predictive value.
A recent meta-analysis that included 20 studies with more than 2800 patients concluded that NBI had a higher sensitivity than WLI for the detection of NMIBC [25 && ]. The pooled additional detection rates of NBI compared with WLI only for NMIBC and CIS diagnosis were 10 and 25% in per-patient analysis and 19 and 31% in per-lesion analysis, respectively. Another recent meta-analysis that included six trials compared the efficacy of resection after NBI and WLI for NMIBC [26 && ]. The use of NBI before TURB was significantly associated with a reduction in the risk of recurrence compared with WLI only at 3 months, 1 and 3 years (all P < 0.01). The latest RCT from the Clinical Research Office of the Endourological Society (CROES), that enrolled nearly 1000 patients, confirmed a lower recurrence rate only in low-risk patients (according to the European Organisation for Research and Treatment of Cancer risk classification). There was no difference in the recurrence rates in the intermediate-risk, high-risk and all-patient groups were similar [27 && ].
STORZ PROFESSIONAL IMAGE ENHANCEMENT SYSTEM
The SPIES technology (Karl Storz, Tuttlingen, Germany) is based on the modular IMAGE1 S camera platform that incorporates four different visualization modes. The Clara provides homogeneous images with clear visibility of darker regions due to the adaptation of local brightness. The Chroma modality increases the sharpness of the images. The Spectra A and Spectra B modalities shift and exchange the effective spectral response in the imaging system, which leads to a better color contrast related to different penetration depths [9 & ]. The four different modalities are proposed to choose the best option according to the specific clinical situation: for example, the Spectra B is suggested in case of interference such as in hematuria, whereas the Spectra A is suggested in case the surgeon desires a higher contrast of the image [28] .
The current technology is relatively new and clinical results are still pending. The first pilot study evaluated the variability in interpretation of the same bladder mucosa image using the four different modalities and WLI [29 & ]. Seventy-three participants were asked to evaluate 80 images from 20 bladder areas. In the images predefined as with low agreement by a panel of specialists, the Clara, Chroma and Spectra B visualizations had fewer variations in interpretation compared with WLI and Spectra A. Based on these findings, the authors recommended using the Clara and Chroma or Spectra B combination during cystoscopy. A RCT endorsed by the CROES in 2015 comparing the recurrence rate in patients treated with SPIES-assisted vs. WLI TURB is still ongoing [30] .
CLINICAL INDICATIONS FOR THE USE OF NOVEL ENDOSCOPIC IMAGING
The latest European Association of Urology (EAU) and American Urological Association guidelines indicate that the use of conventional WLI and voided/bladder-wash cytology remains the standard of care for diagnosis and follow-up assessment of NMIBC [31 && ,32] . However, both guidelines recommend the use of PDD to increase the sensitivity of diagnosing mucosal lesions especially CIS despite the lower specificity compared with WLI [31 && ,32] . The EAU guidelines recommend the use of PDDguided biopsy from normal-looking bladder mucosa and prostatic urethra in patients with positive cytology and negative cystoscopy as well as with tumors with nonpapillary appearance such as flat invasive lesions [31 && ]. Furthermore, the EAU guidelines reported the first promising results of NBI-guided biopsies and resection in terms of improved cancer detection [23, 33, 34] . Finally, the National Institute for Health and Care Excellence guidelines recommend the use of WLI with PDD, NBI, cytology or a urinary biomarker test in patients with suspected BCa.
CONCLUSION
Novel endoscopic imaging is a diagnostically useful tool for evaluating BCa during the cystoscopy and/ or TURB. PDD utilizes metabolic products that increase the sensitivity of detecting bladder lesions especially CIS leading to significantly lower recurrence rates compared with WLI. The impact of PDD on progression-free survival is still unclear. NBI and SPIES are imaging modalities that do not require a preoperative instillation of photosensitizing agents. Recent evidence suggests lower recurrence rate using NBI-guided TURB. However, further trials are necessary to confirm these results, particularly in intermediate and high-risk lesions. RCT assessing the clinical impact of SPIES in BCa patients are ongoing.
It is clear today that WLI is not sufficient to ensure detection of all tumors and that fluorescence endoscopic imaging will become an essential tool to deliver adequate care in NMIBC.
